found Documents: 881

Announcements & Press Releases, Group | 30 Sep 2019

CK Hutchison offers 1.3% of Chi-Med’s share capital aiming to deconsolidate and hold Chi-Med as a strategic investment for the long term

1 item

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: Monday, September 30, 2019: Hutchison Chin

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 30 Sep 2019

Total Voting Rights

1 item

London: Monday, September 30, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at September 30, 2019, the issued share capital of Chi-Med consisted of 666,786,450 ordinary shares of US$0.10 e

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Sep 2019

Chi-Med to Discuss Surufatinib Phase III and U.S. Phase I/Ib Efficacy and Safety Data Presented at the 2019 ESMO Annual Meeting

1 item

Press Release – Surufatinib achieved primary endpoint, reducing the risk of progression or death by 67% in patients with non-pancreatic neuroendocrine tumors (“NET”) in the Phase III SANET-ep study – – Preparations underway for the potent

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 25 Sep 2019

Chi-Med Highlights Presentation of Clinical Data from the Successful SANET-ep Phase III Trial at ESMO Annual Meeting

1 item

– Late-Breaking Abstract of the positive SANET-ep Phase III trial of surufatinib in patients with non-pancreatic neuroendocrine tumors (“NET”) to be presented – – Conference call and webcast with lead trial investigators to be held on Mond

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 18 Sep 2019

Chi-Med Highlights Oral Presentations at 2019 CSCO Annual Meeting

1 item

London: Wednesday, September 18, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) shares additional analyses from three completed and ongoing clinical studies of fruquintinib and savolitinib at the 22nd Annual Meeting of the C

Download Press Release (PDF)

Announcements & Press Releases, Group, Press Releases | 3 Sep 2019

Chi-Med to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference

1 item

London: Tuesday, September 3, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will participate in a fireside chat at Morgan Stanley 17th Annual Global Healthcare C

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 3 Sep 2019

Chi-Med Initiates an International Phase I/Ib Trial of HMPL-689 in Patients with Advanced Relapsed or Refractory Lymphoma

1 item

London: Tuesday, September 3, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated an international Phase I/Ib study of HMPL-689, its novel, highly selective and potent small molecule phosphoinositide-3 kinase delta

Download Press Release (PDF)

Announcements & Press Releases, Regulatory Notice | 30 Aug 2019

Total Voting Rights

1 item

London: Friday, August 30, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at August 30, 2019, the issued share capital of Chi-Med consisted of 666,777,450 ordinary shares of US$0.10 each, w

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 23 Aug 2019

Chi-Med Initiates a Phase I Trial of HMPL-523 in Patients with Immune Thrombocytopenia (ITP) in China

1 item

London: Friday, August 23, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase I study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in patients with immune thrombocytopenia (“ITP”

Download Press Release (PDF)

Announcements & Press Releases, Regulatory Notice | 20 Aug 2019

TR-1: Form for notification of major holdings

1 item

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hut

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 30 Jul 2019

TR-1: Form for notification of major holdings

1 item

View Announcement (PDF)

Announcements & Press Releases, Group | 30 Jul 2019

Chi-Med Reports 2019 Interim Results and Provides Updates on Key Clinical Programs

1 item

London: Tuesday, July 30, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its unaudited financial results for the six months ended June 30, 2019 and provides updates on key clinical programs. Major highlight

CK Hutchison offers 1.3% of Chi-Med’s share capital aiming to deconsolidate and hold Chi-Med as a strategic investment for the long term

Total Voting Rights

Chi-Med to Discuss Surufatinib Phase III and U.S. Phase I/Ib Efficacy and Safety Data Presented at the 2019 ESMO Annual Meeting

Chi-Med Highlights Presentation of Clinical Data from the Successful SANET-ep Phase III Trial at ESMO Annual Meeting

Chi-Med Highlights Oral Presentations at 2019 CSCO Annual Meeting

Chi-Med to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference

Chi-Med Initiates an International Phase I/Ib Trial of HMPL-689 in Patients with Advanced Relapsed or Refractory Lymphoma

Total Voting Rights

Chi-Med Initiates a Phase I Trial of HMPL-523 in Patients with Immune Thrombocytopenia (ITP) in China

TR-1: Form for notification of major holdings

TR-1: Form for notification of major holdings

Chi-Med Reports 2019 Interim Results and Provides Updates on Key Clinical Programs

TR-1: Form for notification of major holdings

TR-1: Form for notification of major holdings

Chi-Med to Announce 2019 Half-Year Financial Results

Blocklisting Six Monthly Return

Chi-Med Announces Pricing of Upsized U.S. Public Secondary Offering of American Depositary Shares

Chi-Med Announces Secondary Offering of American Depositary Shares

Chi-Med Announces that Surufatinib Phase III SANET-ep Study Has Met its Primary Endpoint at Interim Analysis in Advanced Non-Pancreatic Neuroendocrine Tumors in China and Will Stop Early

Block Admission Applications and Total Voting Rights

Disclosure Update

Results of Extraordinary General Meeting

Grant of Share Options under Share Option Scheme

Notice of Extraordinary General Meeting and Shareholders' Circular

Results of Annual General Meeting

Disclosure Update

Chi-Med Files Application to List in Hong Kong and Announces Proposed Global Offering

Chi-Med Initiates a Phase IIb/III Trial of Surufatinib in Patients with Unresectable or Metastatic Biliary Tract Cancer in China

Chi-Med Highlights Oral Presentations on Savolitinib Lung Cancer Programs at AACR Annual Meeting

Vesting of awards under the Long Term Incentive Plan

2018 Annual Report and Notice of Annual General Meeting

Publication of Form 20-F

Chi-Med Reports 2018 Full Year Results and Provides Updates on Key Clinical Programs

Chi-Med Highlights Preliminary Phase II Savolitinib / Imfinzi® Combination Data in Advanced Papillary Renal Cell Carcinoma at 2019 ASCO Genitourinary Cancers Symposium

Chi-Med to Announce 2018 Final Results

Chi-Med to Present at the 37th Annual JP Morgan Healthcare Conference

Blocklisting Six Monthly Return

Total Voting Rights

Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company

Chi-Med Announces Progress in Savolitinib Lung Cancer Program and Update on Kidney Cancer Strategy

TR-1: Form for notification of major holdings

Total Voting Rights

Chi-Med Enters into Multiple Collaborations to Evaluate Combinations of Surufatinib and Fruquintinib with PD-1 Checkpoint Inhibitors

Chi-Med Announces First Commercial Launch of Fruquintinib Capsules (Elunate®)

Chi-Med Receives BayHelix R&D Achievement of the Year Award at BioCentury China Healthcare Summit

Chi-Med Announces Phase III FALUCA Trial Results for Fruquintinib in Third-Line, Advanced Non-Small Cell Lung Cancer in China

Total Voting Rights

Grant of Share Options under Share Option Scheme

Chi-Med Initiates a Phase I Trial of HMPL-523 in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia in China

Appointment of HSBC Bank plc as Joint Corporate Broker in London